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ABSTRACT  
Clinical translation of BCRP inhibitors have failed due to neurotoxicity and novel 
approaches are required to identify suitable modulators of BCRP to enhance CNS drug 
delivery. In this study we examine 18 compounds, primarily phytochemicals, as 
potential novel modulators of AhR-mediated regulation of BCRP expression and 
function in immortalised and primary porcine brain microvascular endothelial cells as a 
mechanism to enhance CNS drug delivery.  The majority of modulators possessed a 
cellular viability IC50 > 100µM in both cell systems.  BCRP activity, when exposed to 
modulators for 1 hour, was diminished for most modulators through significant 
increases in H33342 accumulation at < 10 µM with 2,6,4-trimethoflavone increasing 
H33342 intracellular accumulation by 3.7-6.6 fold over 1-100 µM. Western blotting 
and qPCR identified two inducers of BCRP (quercetin and naringin) and two down-
regulators (17-β-estradiol and curcumin) with associated changes in BCRP efflux 
transport function further confirmed in both cell lines. siRNA downregulation of AhR 
resulted in a 1.75 ± 0.08 fold change in BCRP expression, confirming the role of AhR 
in the regulation of BCRP.  These findings establish the regulatory role AhR of in 
controlling BCRP expression at the BBB and confirm quercetin, naringin, 17-β-
estradiol, and curcumin as novel inducers and down-regulators of BCRP gene, protein 
expression and functional transporter activity and hence potential novel target sites and 
candidates for enhancing CNS drug delivery. 
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1. INTRODUCTION 
The blood-brain barrier (BBB) and the blood-cerebrospinal fluid barrier (BCSFB) are the two 
principal barriers to drug permeation to the central nervous system (CNS). CNS drug delivery 
is often hindered by the complex anatomy and physiology of the brain and CNS 
1
.  
Although this restriction to drug permeation is governed by a complex network of cellular 
communication mechanisms, the expression of a variety of ATP-Binding Cassette (ABC) 
transporter proteins 
2, 3
 significantly enhances the barrier phenotype and contributes to a 
‘gatekeeper’ effect, limiting access of drugs to the brain and CNS biophase. An important 
member of the ABC family of transporters is the breast cancer resistance protein 
(BCRP/ABCP/MXR) 
4-6
.  BCRP is a 655-amino acid, 72 kDa protein containing a single 
nucleotide binding domain (NBD) with six transmembrane domain (TMD) regions and is 
localised to a range of sanctuary site tissues.  The transcriptional regulation of BCRP at the 
BBB, as with many ABC transporters, is thought to be governed by a range of nuclear 
hormone receptors 
7, 8
 and the interference of these signalling pathways under physiological 
and pathophysiological conditions provides a new approach to modulate BCRP function at 
the CNS barrier 
9-11
. The aryl hydrocarbon receptor (AhR) has been reported to be highly 
expressed in brain microvessels 
12-14
. The prototypical ligand for the induction of AhR 
activity are dioxins such as the 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and induction of 
AhR activity by TCDD was first studied in hepatic cells 
15
.  AhR is therefore an important 
regulatory element in controlling the homeostatic balance of xenobiotic transporter/clearance 
pathways, but is also a potentially important target for modulating the expression of drug 
transporter proteins such as BCRP at the BBB, with a view to enhancing the delivery of 
therapeutic agents into the CNS
14
. Inhibitors of BCRP have been developed and studied in 
human trials with poor clinical efficacy because of significant toxicity and drug-drug 
interactions 
16-18
. Recently phytochemicals have gained interest as potential candidates for 
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drug transporter inhibition, but which also demonstrate a relatively wide safety/toxicity 
profile.  Phytochemicals, of which flavonoids are the most widely cited, are polyphenolic 
compounds that are widely ingested in the diet of humans and which can be found in fruit, 
vegetables and herbal products.   The dietary ingestion of flavonoids results in the exposure 
of the gastrointestinal system to the glycoside conjugate form of the flavonoids, which often 
possess limited absorption into the systemic circulation 
19
. Within the stomach and small-
intestine, these glyosidic forms come into contact with lactase phloridzin hydrolase (LPH), 
which results in an aglycone form of the flavonoids which is then absorbed by passive 
diffusion 
20
.  It is therefore unlikely that the conjugated form of the flavonoids would 
naturally be capable of crossing the BBB. 
Recently we demonstrated that phytochemicals were capable of modulating the expression 
and function of BCRP at the BCSFB 
21
.  The aim of the present study is threefold: (i) 
investigate the impact of phytochemical modulators on the genomic and protein expression of 
BCRP in immortalised porcine brain microvascular endothelial cells; (ii) assess the functional 
consequences of modulation of BCRP efflux transport in a primary porcine brain 
microvascular endothelial cells; (iii) investigate the role of phytochemicals in modulating 
AhR-mediated transcriptional regulation of BCRP.  
2. RESULTS  
2.1 Expression and localisation of BCRP in PBMEC/C1-2 and primary cells 
The expression of BCRP in both cell lines was confirmed by reverse-transcriptase PCR with 
an expected amplicon product of 653 bp (Figure 1A).  Furthermore localisation of BCRP was 
observed in PBMEC/C1-2 grown on coverslips (Figure 1B) and primary PBMEC grown on 
permeable inserts (Figure 1C).  
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2.2 Modulator induced cellular toxicity  
To investigate the cellular toxicity of modulators towards the PBMEC/C1-2 cells, a MTT 
cellular toxicity assay was conducted whereby cells were exposed to a 7-fold log 
concentration range of modulators, 0.001 µM-1000 µM, for 24 hours. Modulators 
demonstrated a range of toxicities towards PBMEC/C1-2 cells (Figure 2). The lowest IC50 
(1.5 ± 2.7 µM) was observed for α-napthoflavone. Similarly, baiclain, 17-β-estradiol, 
hesperidin and hesperetin demonstrated low micromolar IC50 with the majority of modulators 
demonstrating minimal toxicities in the range of 100-1000 µM (Figure 2).  The cellular 
toxicity of modulators towards the primary PBMEC was also investigated using MTT 
toxicity assay. Cells were exposed to 25 µM and 100 µM of modulators for 24 hours. Similar 
trends were observed as for PBMEC/C1-2 with α-napthoflavone showing significant 
cytoxicity at 25 µM and 100 µM in addition to 25 µM of curcumin (31.9 ± 9.8 % viability) 
and 17-β-estradiol (28.3 ± 7.2 % viability) (Figure 3). Additionally, a number of modulators 
demonstrated minimal toxicities up to 100 µM and included apigenin, biochanin A, chrysin, 
fistein, flavone, I3C, naringin, quercetin, resveratrol, rutin, silymarin and TMF (Figure 3).  
Modulator concentrations of 25 µM were utilised for subsequent assays, except for curcumin, 
17-β-estradiol, α-napthoflavone, baicalin, hesperetin and hesperedin (1 µM upper limit)   
2.3 Hoechst 33342 intracellular accumulation assay  
The functional activity of BCRP was evaluated by measuring the intracellular accumulation 
of a fluorescent BCRP substrate (H33342) in PBMEC/C1-2 cells following co-incubation in 
the presence of modulators and the specific BCRP inhibitor Ko143. Studies were conducted 
to assess the potential for inhibtion of BCRP efflux fuction (1-hour incubation) and for 
modulation of BCRP-protein expression (24-hour incubation).  All modulators were screened 
for their inherent auto-fluorescence at the λex/em for H33342 and three were excluded 
(baicalin, fisetin and α-napthoflavone). 
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Our results demonstrated a concentration dependant increase in H33342 for most modulators 
studied, across a concentration range of 1-100 µM, when incubated for 1 hour (Figure 4A). 
Furthermore, the fold change in H33342 intracellular accumulation was equal to or greater 
than that observed for Ko143 (represented by the grey shaded area in figure 4A) for apigenin 
(1-100 µM), hesperidin (100 µM), I3C (1-100 µM) and 2,6,4-trimethoxyflavone (TMF) (1-
100 µM) and leading to an increase in H33342 accumulation by 1.8-2.3 mean fold range, 2.4 
± 0.5 fold change, 2.3-4.1 mean fold range and 3.7-6.6 mean fold range respectively when 
compared to the absence of modulators.  
 
Time dependent functional activity of BCRP was also evaluated following incubation of 
H33342 in the presence of modulators for a 24 h period.  Our results demonstrated that 
incubation with biochanin A (10-100 µM), chrysin (1-100 µM), curcumin (0.1-1 µM),17-β-
estradiol (0.01-1 µM), I3C (10 µM and 100 µM), silymarin (1-100 µM) and TMF (10-
100µM) resulted in a significant increase in intracellular H33342 accumulation when 
compared to control (Figure 4B) and in a concentration-dependant manner. Furthermore, a 
significant reduction in H33342 accumulation was observed with hesperetin and hesperidin 
(0.5-0.8 mean fold change), naringin (0.37-0.48 mean fold change) and quercetin (0.75-0.46 
mean fold change) when compared to control across all concentration studied, primarily in a 
concentration-dependant manner and generally to a similar extent as that observed with the 
BCRP inducer TBhQ (Figure 4B). 
2.4 Modulation of BCRP expression  
To assess the impact of modulators on the protein expression of BCRP, PBMEC/C1-2 cells 
were exposed to modulators for 24 hours and changes in protein expression were assessed 
through western blotting. BCRP protein (monomer) was confirmed with a product size of 72 
kDa (Figure 5A).  Significant induction (p ≤ 0.05) of BCRP protein was observed for 
9 
 
biochanin A (0.42 ± 0.10 fold), hesperetin (0.51 ± 0.14 fold), hespiridin (0.78 ± 0.21 fold), 
naringin (1.2 ± 0.05 fold) and quercetin (1.25 ± 0.07 fold) (Figure 5B and C).  Furthermore, 
at the transcription level, these changes were confirmed with quercetin and naringin 
significantly (p < 0.0001) up-regulating BCRP expression by 1.63 ± 0.28 and 1.36 ± 0.71 fold 
(Figure 6A).   
Significant (p ≤ 0.001) down-regulation of BCRP protein was observed with curcumin (1.75 
± 0.22 fold), 17-β-estradiol (1.23 ± 0.19 fold) and less so with TMF (0.56 ± 0.10 fold) (p ≤ 
0.01) (Figure 6A) and confirmed with similar changes in BCRP gene expression (curcumin: 
1.78 ± 0.05 and 17-β-estradiol: 1.54 ± 0.05) (Figure 6A).  Confirmation of BCRP induction 
was evident with TBHQ (positive control) yielding a 1.29 ± 0.12 fold increase in BCRP 
protein expression. 
 
2.5 AhR mediated regulation of BCRP in PBMEC/C1-2 cells 
To confirm the role of AhR in the transcriptional regulation of BCRP, gene silencing of AhR 
(AhR targeting siRNA) and antagonism of AhR activity (CH223191
22
) was conducted to 
assess changes in both AhR and BCRP expression by qPCR approaches.  Using both a 
chemical antagonist of AhR and AhR-targetted siRNA, we demonstrated successful down-
regulation of BCRP and AhR in PBMEC/C1-2 cells. CH223191 at 1 µM and 10 µM resulted 
in no significant reduction in AhR expression but a significant 2.31 ± 0.08 fold down-
regulation with siRNA (p ≤ 0.01) (Figure 6B).  BCRP gene expression was also quantified in 
the same samples that were treated with CH223191 and demonstrated down-regulation when 
exposed to 1 µM (p ≤ 0.001) and 10 µM (p ≤ 0.05) leading to a 1.12 ± 0.09 and 0.79 ± 0.12 
fold change respectively. In samples exposed to dicer AhR siRNA, BCRP gene expression 
was also significantly down-regulated (p < 0.01) leading to a 1.75 ± 0.08 fold change (Figure 
6B). 
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2.6 Phytochemical mediated modulation of AhR and BCRP gene expression  
To assess whether phytochemicals were able to modulate the expression of AhR, siRNA 
techniques were used to silence AhR and assess subsequent changes in AhR expression 
following incubation with modulators in PBMEC/C1-2 cells.  
In the absence of siRNA, AhR was significantly increased (p ≤ 0.0001) when exposed to 
BCRP protein inducers quercetin (0.62 ± 0.31 fold) and naringin (0.84 ± 0.08 fold), relative 
to control samples (Figure 6C). However for BCRP protein down-regulates curcumin and 17-
β-estradiol, no significant differences in AhR was detected (Figure 6C). 
When cells were exposed to siRNA, AhR gene expression was significantly reduced 
(compared to control samples), when exposed to BCRP protein inducers quercetin (1.26 ± 
0.06 fold) (p ≤ 0.0001) and naringin (0.64 ± 0.08 fold) (p ≤ 0.05). Additionally, significant 
differences existed when compared the absence and presence of siRNA (p < 0.0001). 
Furthermore, AhR gene expression was significantly reduced when exposed to BCRP protein 
down-regulators curcumin (1.06 ± 0.09 fold) (p ≤ 0.01) and 17-β-estradiol (0.97 ± 0.09 fold) 
(p ≤ 0.01 (Figure 6C).  However, no significant difference was detected when comparing 
samples in the absence or presence of siRNA (Figure 6C). 
 
In the absence of AhR-targetting siRNA, BCRP was significantly increased (P ≤ 0.0001) for 
BCRP protein inducers, namely quercetin (1.63 ± 0.28 fold) and naringin (1.36 ± 0.71 fold), 
relative to control samples (Figure 6D). Similarly, BCRP protein down-regulators 
demonstrated significant decrease in BCRP, curcumin (1.78 ± 0.05 fold) (P ≤ 0.0001) and 17-
β-estradiol (1.54 ± 0.05 fold) (P ≤ 0.01) (Figure 6D).  When AhR was silenced, BCRP was 
reduced compared to control samples for BCRP protein inducers, quercetin (0.18 ± 0.12 fold) 
and naringin (0.41 ± 0.09 fold) and were not significantly different from control (absence of 
modulators) (Figure 6D)  but were significantly different from results obtained for BCRP 
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expression in the absence of siRNA. For BCRP protein down-regulators, BCRP expression 
increased when compared to samples in the absence of siRNA for curcumin (0.62 ± 0.10 
fold) and 17-β-estradiol (0.22 ± 0.21 fold) but were not significantly different from control 
(absence of modulators) (Figure 6D).  Furthermore, when compared to samples in the 
absence of siRNA significant differences between –siRNA and +siRNA samples existed for 
curcumin (P ≤ 0.01) and naringin (P ≤ 0.05) (Figure 6D).   
2.7 Activation of AhR by modulators in H1L6.1c2 cells  
To confirm the activation of AhR by modulators, a chemically-activated luciferase (CALUX) 
assay was employed using the stably transfected luciferase H1L6.1c2 cell line to screen 
modulators known to modulate BCRP protein expression in PBMEC/C1-2 cells, relative to 
the maximum activation from incubation with omeprazole (data not shown).  
Modulators identified as ‘strong’ AhR activators (>75 % maximum activation relative to 
omeprazole) included hesperidin (76.09 % ± 4.3 %), naringin (75.54 % ± 1.8 %) and 
quercetin (73.75 % ± 4.6 %).  Modulators with ‘minimal’ activation of AhR included 
biochanin A, curcumin, 17-β-estradiol, reservatrol and rutin. All other flavonoids 
demonstrated a greater than 25 % but less than 75 % maximum luciferase induction (when 
considering the SD) (Figure 7).  
2.8 Phytochemical mediated modulation of BCRP transporter function  
The function of BCRP in a representative in vitro BBB model was assessed by measuring the 
transport of PhA in the absence and presence of Ko143, a known BCRP inhibitor. Our results 
demonstrated that 1-hour incubation with Ko143 (1 µM) significantly increased the apical-to-
basolateral (AB) flux and decreased the basolateral-to-apical (BA) flux of PhA during our 
transport studies (p < 0.05) in both cell systems (Table 1).  The calculated efflux ratio (ER) 
for PBMEC/C1-2 and PBMEC were 5.6 and 11.2, respectively, in the absence of Ko143 and 
1.7 and 1.6 in the presence of Ko143. 
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The functional assessment of BCRP following modulator exposure was evaluated in the 
presence of BCRP down-regulators (curcumin and 17-β-estradiol). Our results demonstrated 
that 24 hour incubation of curcumin and 17-β-estradiol significantly increased the apical-to-
basolateral (AB) passive permeability (Papp,AB) (Table 1) of PhA in both PBMEC/C1-2 and 
PBMEC (Figure 8A).   Incubation with curcumin resulted in a 5-fold increase in AB flux for 
PBMEC/C1-2 but a larger 6.2-fold increase in AB flux for PBMEC (Figure 8B).  For 17-β-
estradiol a 4.1-fold increase in AB flux for PBMEC/C1-2 and 6.9 fold increase in AB flux for 
PBMEC (Figure 8B).  Furthermore, our results demonstrated that 24-hour incubation with 
naringin and quercetin (25 µM) increased the basolateral-to-apical (BA) flux of PhA (Table 
1) by 1.3-fold and 1.07-fold in PBMEC/C1-2 and PBMEC cells and 1.4-fold and 1.20 fold in 
PBMEC/C1-2 and PBMEC for quercetin (Figure 8C). 
3. DISUCSSION 
3.1 Phytochemical toxicity at the BBB  
Our results demonstrated that the majority of modulators exhibited IC50 values in excess of 
100 µM in PBMEC/C1-2 (Figure 2) and limited toxicity at 25 µM in PBMEC (Figure 3). 
However, a number of modulators demonstrated low IC50 values ranging from 1.5 - 63 µM 
and included flavones such as baiclain, flavone, α-napthoflavone and flavonones such as 
hesperidin and hesperetin, 17-β-estradiol and curcumin.  In most instances, the concentration 
employed within the study were below the cytotoxicity IC50, and when considering that brain 
concentrations of flavonoids are typically < 50 µM 
23-25
, the inherent toxicity towards the 
BBB endothelium would be minimal.  Furthermore, whilst difficult to compare with reported 
studies, the IC50 values determined for modulators were found to be within the same order of 
magnitude as published reports from, often, non-cerebral origin cell lines 
26-31
.  
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3.2 Intracellular accumulation of Hoechst 33342  
The fluorescent properties of H33342 make it an ideal tool to use during the study of its 
intracellular accumulation when modulating the function of BCRP, and has widely been used 
as a BCRP substrate.  Our results demonstrated both inhibition of BCRP efflux function 
(Figure 4A) and potentially genomic/proteomic level alteration of BCRP efflux function 
following prolonged incubation (Figure 4B).  Furthermore, the results demonstrated that 
TMF is a potent modulator of BCRP function with a 3.70 ± 0.39 fold change in H33342 
accumulation compared to control at the lowest concentration studied, 1 µM (Figure 4A).  Of 
the published reports available, TMF has been identified as potent inhibitor of BCRP efflux 
activity at the BBB having also been identified in BCRP-transduced human leukaemia K562 
cells 
32
. Furthermore, of the published reports available, curcumin has been reported to inhibit 
BCRP function in HEK293 cells without altering protein levels over 72-hours of incubation 
nor inhibiting the ATPase function of the NBD 
33
. Furthermore, it has recently been 
recommended that curcumin be used as the ‘best’ in vivo inhibitor of BCRP 
34
.   Our results 
also demonstrated that 17-β-estradiol increased H33342 accumulation in a concentration 
dependant manner with the greatest increase observed at 1 µM, 1.51 ± 0.21 fold (p ≤ 0.01), 
and has been widely reported inhibitor of BCRP function 
9, 35
.   
During prolonged incubation the majority of phytochemicals demonstrated some level of 
concentration-dependant modulatory effects leading to statistically significant increases or 
decreases in H33342 accumulation compared to control (Figure 4B). Of note were naringin 
(10-100 µM), quercetin (10-100 µM), hesperetin and hesperidin (1 µM) which resulted in a 
reduction in H33342 accumulation to within the reported by the positive control inducer 
THBQ and suggesting these modulations possess BCRP down-regulatory properties.  
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These finding indicate that modulators may play a role in directly inhibiting BCRP at the 
BBB during short-term incubations. The exact mechanism of BCRP inhibition is not clear. 
But it has been reported that glycosylated flavonoids have anti-BCRP activity due to their 
water solubility 
36
. Modulators lacking significant inhibitory activity may be hindered by 
their low lipophilicity and reduced permeability. This may explain why we observed no 
inhibitory effects for resveratrol and rutin which are glycosides and have lower lipophilicity 
compared with their respective aglycones 
37
.  Furthermore, the binding of flavonoids to the 
nucleotide-binding domain of BCRP has been identified as being important the inhibition 
process 
32, 38
, leading to inhibition of the ATPase function and hence halting of the 
conformational changes required to transport substrates across the cell membrane. 
Additionally QSAR analyses have demonstrated a strong structure-inhibition relationship 
between BCRP and flavonoids. Flavonoids with a hydroxyl group at position 5, double bond 
between position 2 and 3 and methoxyl moiety at position 3 or 6 
39
 show preference for 
binding to BCRP and inhibiting the functional transport. This may explain why the greatest 
intracellular accumulation of H33342 was observed with TMF, as O-methylation at position 
2, 4 and 6 increases the local hydrophobicity and hence signifies TMF mediated anti-BCRP 
activity.    
It should be noted that H33342 is also a substrate of P-glycoprotein, and concentration-
dependant differences in intracellular H33343 accumulation, such as those identified with 
apigenin and TMF, may be attributed to inhibition of P-gp.  Nevertheless, the H33342 
intracellular accumulation studied aided in identifying potential modulators of BCRP 
function, which were further validated at a genomic and proteomic level through qPCR and 
western blotting analysis. 
15 
 
Furthermore, the mechanism of BCRP modulation following prolonged incubation was 
further assessed in subsequent studies investigated both genomic and proteomic level effects 
coupled with the role of the nuclear hormone receptor AhR, in BCRP regulation. 
3.3 Modulation of BCRP protein expression  
BCRP protein (Figure 5) and gene (Figure 6) expression was successful confirmed in both 
PBMEC/C1-2 and primary PBMEC cells.  Whilst previous reports have identified 
phytochemicals as being able to modulate BCRP protein in non-cerebral cell lines 
40
, we 
identified two phytochemicals capable of inducing BCRP expression at the BBB, namely 
narinign and quercetin (Figure 5C) and two phytochemicals capable of down-regulation 
BCRP expression at the BBB, curcumin and 17-β-estradiol (Figure 5C), which also 
demonstrates some similar correlations with our 24-hour H33342 intracellular accumulation 
studies (Figure 4B), despite the differing end-point analytic metrics.   
Furthermore, previous studies have reported similar observations and confirm our choice of 
naringin
21, 41
, quercetin
40
, curcumin
34
 and 17-β-estradiol 
35,9
 as viable BCRP modulators and 
support our identification and selection of BCRP-modulatory phytochemicals. 
3.4 AhR mediated regulation of BCRP in PBMEC/C1-2 cells 
The relationship between AhR and its transcriptional regulation of BCRP was also identified 
by Tompkins et al 
42
, who reported that activation of BCRP expression in human colon 
adenocarcinoma-derived LS174T cells is regulated by AhR.  To identify whether AhR would 
be a potentially novel target for modulation of BCRP function we assessed the role of Aryl 
Hydrocarbon Receptor (AhR) in regulator BCRP expression at the BBB.  Through 
pharmacological antagonism and gene silencing (siRNA) of AhR, BCRP gene expression 
was significantly downregulated under all treatment conditions (Figure 6B) with statistically 
significant differences in AhR and BCRP expression under CH223191 and siRNA treatment 
when compared to control (untreated: fold-change = 0).  Previously, only one study has 
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reported the modulation of BCRP through AhR dependent manner in Caco-2 cells 
43
, and 
taken together our results confirm that AhR plays a significant role in the transcriptional 
regulation of BCRP.  
3.5 Phytochemical mediated modulation of AhR and BCRP gene expression  
Having confirmed the role AhR plays in regulating the expression of BCRP, the identified up- 
and down-regulators of BCRP gene/protein expression were assessed against AhR silenced 
cells and it was confirmed that silencing of AhR abolished the induction/down-regulation 
effect elicited by phytochemicals in the absence of siRNA (Figure 6D). For the up-regulators, 
the lack of statistically significant differences between control and + siRNA for changes in 
BCRP expression highlight a ‘normalisation’ of BCRP gene expression as it returns to 
baseline and hence no significant difference in gene expression compared to control. 
Similarly curcumin and 17-β-estradiol were identified as down-regulators of BCRP and when 
AhR is silenced  BCRP expression recovers to 0.51 ± 0.09 and 0.29 ± 0.19 of control and is 
not significantly different from control, again suggesting a return to baseline expression for 
BCRP (Figure 6D).  
At the BBB this confirms that AhR has a significant role to play in the regulation of BCRP, 
and is supported by a recent study by Wang et al 
14
. Furthermore, the modulators identified as 
up- or down-regulators of BCRP expression may, in part, act to impact directly upon the 
activity of AhR, such as nuclear translocation 
44
 
45
, as a possible mechanism which can alter 
the gene expression of BCRP. 
3.6 Activation of AhR by modulators in H1L6.1c2 cells  
We selected the stably transfected H1L6.1c2 cell lines along with an associated luciferase 
assay based on the CALUX assay developed by He et al 
46
 to assess whether modulators were 
capable of modulating AhR by activating a luciferase response following a period of 24 h 
incubation in H1L6.1c2 cells.  All modulators demonstrated some degree of activation of 
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AhR, with hesperidin, naringin and quercetin identified as ‘strong’ activators, and the 
majority of modulators yield a reduction in H33342 intracellular accumulation being 
identified as ‘minimal’ activators of AhR activity (Figure 7).  It has been reported that 
quercetin significantly increased AhR activity by inducing CYP1A1 in human hepatoma 
HepG2 cells, whereas rutin a glycoside of quercetin failed to induce AHR and activation of 
CYP1A1 
47
 when incubated with similar concentration (10-50 µM) 
47
. Additionally, other 
studies have also confirmed AhR activation by similar modulators identified in our studies.  
For example quercetin has been shown to activate AhR mediated CYP1A1 mRNA expression 
in Caco-2 cells 
48, 49
 and MCF-7 cells 
50
 at concentrations of 0.5-10 µM. Another study also 
reported that chrysin, baiclain, galangin and genistein induced the luciferase activity in stably 
transfected Hepa-1 cells whereas quercetin, emodin and apigenin demonstrated inhibitory 
effect on AHR induction relative to TCDD and act in a concentration dependant manner 
51
. 
Taken together, this demonstrates that phytochemicals are capable of activating the AhR 
regulator pathway which can (in the case of the identified modulators) directly impact upon 
the gene and protein expression BCRP.   
3.7 Phytochemical mediated modulation of BCRP transporter function  
Whilst gene or protein changes in BCRP expression may suggest at a possible change in the 
functional expression of BCRP, without conducting transport studies using a BBB monolayer 
model, the consequences of any gene/protein level changes in BCRP cannot be assessed in a 
functional sense.  Across both PBMEC/C1-2 and primary cell culture model we identified 
similar behaviours of induction or down-regulation of BCRP expression and the functional 
consequences of this was confirmed using the permeable insert models. Our results 
confirmed that BCRP is expressed in PBMEC/C1-2 cells and primary porcine brain 
microvascular endothelial cells.   
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By comparing both immortalised and primary, the impact on BCRP transporter function in 
the low TEER PBMEC/C1-2 model can be compared with the higher TEER primary PBMEC 
model. In addressing the low TEER values for PBMEC/C1-2, these cells have been reported 
to retain several BBB properties such as the presence of glucose transporter (GLUT-1), γ-
glutamyltranspeptidase (γ-GT) and apolipoprotein A-1 along with the presence of the von 
Willebrand factor (vWF), lectin binding receptors for UEA-1 and uptake of acetylated LDL 
52
.  Furthermore the induction of cellular tightness by astrocytic factors also contributes to the 
barrier function 
53
 typically giving TEER values similar to that of the human immortalised 
hCMEC/d3 BBB cell line (30-60 Ω.cm
2
 ) 
54, 55
.  Therefore, the model presents a viable one 
with which to study BBB phenotype 
56, 57
 and are augmented by the observations in primary 
PBMEC, the findings of which suggest that 17-β-estradiol and curcumin are viable down-
regulators and quercetin and naringin are viable inducers of BCRP expression and efflux 
function. This has clear implications for modulating the efflux role of BCRP at the BBB 
towards either clearing agents from the brain biophase back into the systemic blood or 
forcing equilibrium towards enhanced brain delivery of therapeutic compounds.  Further 
work is required to address the potential in-vivo translation of this effect in the presence of 
the plasma biophase (and associated plasma proteins) which may hinder phytochemical BBB 
penetration. However, although brain concentration of many phytochemicals are lacking in 
the literature, curcumin has been reported at brain tissues concentrations of 0.4 ± 0.01 µg/g 
58
  
and 2.9 nmol/g 
59
 following a 100 mg/kg dose in mice; Cmax of 13 ± 12 ng/g 
60
 following a 23 
mg/kg oral dose; Cmax of 5.87 µg/brain (~ 2.92 µg/g) following an oral dose of 500 mg/kg 
61
. 
Following a 5 mg/kg intravenous dose of nanoparticle formulated curcumin, regional brain 
tissue concentration of curcumin ranged from 40-165 ng/g (~0.5 µM) 
62
. For naringin, a Cmax 
of 1-2 µg/mL (~2-4 µM) was reported following a 30 and 100 mg/kg intravenous dose in rats 
63
.  Furthermore, for quercetin concentrations of 22.91± 3.35 µg/mL (~45 µM) have been 
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reported in rat brains following an oral dose of 50mg/kg 
64
.  Furthermore, this increased to 
33.28 ± 1.27  µg/mL following the administration of a nanoformulation of quercetin 
64
. 
Although the majority of pharmacokinetics studies assessing plasma or brain concentrations 
of phytochemical modulators have utilised oral routes, the BBB would be limited due to poor 
absorption through the gastrointestinal tract 
20, 65
 and the use of nanoparticle formulation 
systems would be a viable route with which to parenterally deliver the identified 
phytochemical modulators to the BBB at brain vasculature concentrations capable of 
modulating BCRP expression and function. 
4. CONCLUSIONS 
Drug delivery to the CNS has become a major challenge due to the presence of the BBB and 
associated insidious network of drug efflux transporters, which together acts as a physical and 
metabolic barrier for the transport of therapeutic agents into the wider CNS.  Phytochemical 
modulators, primarily flavonoids, were demonstrated to possess limited cellular toxicity 
towards immortalised and primary PBMEC and functional inhibition the efflux activity of 
BCRP, with TMF identified as a potentially potent flavonoid-based inhibitor of BCRP 
activity.  Furthermore, quercetin and naringin were identified as inducers with curcumin and 
17-β-estradiol as down-regulators of BCRP gene and protein.  The role of AhR in both 
directly regulating BCPR expression and mediating modulator-induced changes in 
transcriptional regulation of BCRP function was also identified.  Therefore, phytochemicals 
can be considered to be a potentially useful class of compounds possessing multifaceted 
activity towards the goal of negating BCRP efflux at the BBB or enhancing the efflux 
potential for the removal of agents from the CNS. 
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5. MATERIALS AND METHODS 
5.1 Materials 
Dulbecco’s modified essential media with glucose (DMEM), fetal bovine serum (FBS), 
penicillin/streptomycin and gentamycin were obtained from Biosera (Sussex, UK); 
resveratrol and Ko143 from Santa Cruz Biotechnology (Texas, USA); curcumin from 
Cayman Chemical (Cambridge, UK); premium fetal bovine serum was obtained from Fisher 
Scientific (Loughborough, UK); rat tail I collagen solution from First Link (Birmingham, 
UK) and all other chemicals were sourced from Sigma (Dorset, UK). GenElute Total RNA 
extraction kits were purchased from Sigma (Dorset, UK); My Taq
TM
 one-step RT-PCR kit 
and Easy Ladder I obtained from Bioline (London, UK). All RT-PCR primers and siRNA 
duplexes were designed synthesised by IDTDna (Leuven, Belgium); Luciferase Assay 
System was obtained from Promega (Wisconsin, USA); Optiblot SDS-page gel and western 
blot reagents obtained from Abcam (Cambridge, UK); qPCR gene primers were custom 
synthesised by PrimerDesign (Southampton, UK); Anti-BCRP antibody was obtained from 
Sigma (Dorset, UK), beta-actin (C4), broad range markers, goat anti-rabbit IgG-FITC, RIPA 
buffer and protease inhibitor cocktail were obtained from Santa Cruz Biotechnology (Texas, 
USA).  Stock solutions of all test compounds were prepared in dimethylsulfoxide (DMSO) 
and stored at -20°C until use. 
5.2 Cell culture: immortalised porcine BMEC 
The immortalised porcine brain microvascular endothelial cell line PBMEC/C1-2 was a kind 
gift from Dr P. Friedl 
66
.  PBMEC/C1-2 were grown in conditioning media obtain from rat C6 
astrocytes. C6 cells were obtained from Cell Line Services (Germany). The cells were 
resuspended in a T25 flask containing C6 media (Hams F12 50%, IMDM 50%, 7.5% NCS, 
7mM L-glutamine, 5μg/mL transferrin, 0.5 U/mL heparin and 100 U/mL penicillin G 
sodium, 100 μg/mL streptomycin sulphate). Cells were grown at 37°C in a humidified 
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atmosphere of 5% CO2 for 24 h and media changed after 24 h. Thereafter the cells were 
passaged 3-4 days post seeding (at 70-80% confluency) by washing with pre-warmed PBS 
followed by the addition of 1 mL of trypsin-EDTA to the flask. 
The flask was then placed in an incubator for 5 min and cell suspension was resuspended in 5 
mL of growth media. Cell suspensions were then transferred to a 15 mL centrifuge tube and 
centrifuged at 1500 rpm for 5 min and the pellet was resuspended in 2 mL of the media and 
transferred to a T75. The media was aspirated every other day, sterile filtered (0.22 μm) and 
stored at 4°C for further use. 
This media was labelled as astrocyte conditioning media (ACM).  Subsequently, ACM was 
mixed in a 1:1 with C6 media to develop the maintenance media for PBMEC/C1-2 
52, 56, 66, 67
 
and this was termed C12 media.   
5.3 Cell culture: primary porcine BMEC 
Porcine brain endothelial cells were isolated according to the methods described by 
Patabendige et al (2013) 
68
. Porcine brains were acquired from a local abattoir (Long 
Compton Abbatoir, Oxford, UK) within 1-hour of sacrifice. The brains were transferred to 
the laboratory in sterile box containing L-15 media supplemented with 1 % v/v 
penicillin/streptomycin on ice. Each brain was separated into respective hemispheres and 
thoroughly washed with ice-cold PBS media supplemented with 1 % v/v 
penicillin/streptomycin. The meninges and blood vessels were removed along with the 
choroid plexus and capillaries located within brain sulci. The hemispheres were then placed 
in a clean beaker containing PBS supplemented with HEPES (10 mM) and 
penicillin/streptomycin sulphate. White matter was then carefully removed and grey matter 
dissected and transferred to a beaker containing MEM supplemented with HEPES (10 mM) 
and 1% v/v penicillin/streptomycin. The grey matter tissue was then chopped into small 1 
cm
3
 sections using a sterile scalpel before being transferred into a 50 mL syringe and passed 
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into a T75 containing 50 mL of MEM supplemented with HEPES (10 mM) and 1 % v/v 
penicillin /streptomycin. 15 mL of this brain extract was transferred into a homogeniser 
(Dounce Homogeniser, Jencons, UK) and 25 mL of MEM supplemented with HEPES (10 
mM) and 1 % v/v penicillin/streptomycin sulphate was added to the homogeniser. The brain 
extract was then homogenised gently for 15 strokes with a loose pestle (Type B) followed by 
15 strokes with tight pestle (Type A).  The resulting homogenate was then transferred to a 
sterile T175 and process repeated for the remaining tissue. 
200 mL of homogenate was then filtered through a 150 µm pore nylon mesh and the filtrate 
collected and subsequently filtered again through a 60 µm pore nylon mesh (Plastok 
Associates Ltd, Wirral, UK). The filters were removed and placed into separate 15 cm Petri 
dishes containing 80 mL of digest mix (M199 containing collagenase (223 U/mg), trypsin 
(211 U/mg), DNase I (2108 U/mg), 10 % v/v FCS and 1 % v/v penicillin/streptomycin).  
Filters were then incubated at 37°C for 1 hour in an orbital shaker and labelled as ‘150s’ and 
‘60s’.  
Thereafter the filters were thoroughly washed and the digest mix transferred to 50 mL 
centrifuge tubes labelled ‘150s’ and ‘60s’ and centrifuged at 4°C for 5 minutes at 240 g. The 
pellet was resuspended in 10 mL of MEM supplemented with HEPES (10 mM) and 1 % v/v 
penicillin /streptomycin sulphate and centrifuged again at 4 °C for 5 minutes at 240 g. This 
was repeated 3 times. The final pellets were resuspended in cryopreservation media (90 % 
FBS and 10% DMSO) and cryovials maintained at -80°c for 24 hours before being 
transferred to liquid nitrogen (-196°C) for long term storage until use.   
5.4 Development of in-vitro BBB permeable insert models 
For PBMEC/C1-2, 1 x10
5
 cells/cm
2
 were seeded onto collagen coated (5 µg/cm
2
) 12-well 
inserts (Greiner ThinCert®) and maintained in a 1:1 mixture of C12 media and astrocyte 
conditioning media (ACM), termed C12-ACM, and supplemented with 1 μg/mL fibronectin, 
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to support the development of an appropriately tight endothelial monolayer.  Cells were used 
in transport studies when the trans-endothelial electrical resistance (TEER) was > 50 Ω.cm
2
 
53, 66, 69
. ACM was obtained from the supernatant of rat C6 glioma cells grown in C12 media 
in T75 flasks.  The supernatant was sterile filtered (0.22 μm filter) and stored at 4 °C.  
For primary PBMEC 1 x10
5
 cells/cm
2
 (‘60s’) were seeded into permeable inserts (Greiner 
ThinCert™, pore size 1 µm) that had been pre-coated with 300 µg/mL collagen for 3-4 hours 
in a laminar air hood, and maintained in basic growth media to attach for 24 hours. To 
enhance the formation of the monolayer, the cell culture media was switched on day 4 to 
serum free media supplemented with 250 µM CPT-cAMP, 17.5 µM RO20-1724 and 500 nM 
of hydrocortisone 
70, 71
 and TEER values used to assess the development of a tight monolayer 
with an acceptable cut-off of > 800 Ω.cm
2
 
68
.  
 
For both cell systems, monolayer formation was deemed acceptable using the TEER value 
criteria alongside < 1 % lucifer yellow (LY) permeation across monolayers. For TEER 
measurements, a chop-stick electrodes (EVOM, World Precision Instruments, USA) was 
used and corrected for background resistance (coated inserts without cells) and by the surface 
area of the insert (1.12 cm
2
).  The LY permeability assays were conducted in inserts apically 
exposed to 100 µM of LY prepared in HBSS, for 60 minutes at 37 °C.  The basolateral 
permeation was assessed using a fluorescent plate reader (SpectraMax MX5 reader: 
Molecular Devices LLC, Sunnyvale, CA), with an excitation wavelength of 485 nm and 
emission of 530 nm. 
5.5 Cell culture: murine H1L6.1c2 
The stably transfected AhR-responsive luciferase reporter gene cell line (H1L6.1c2) was 
obtained as a gift from Professor M. Denison 
72
.  Cells were grown to confluency in 75 cm
2
 
flasks in α-MEM supplemented with 10 % (v/v) premium fetal bovine serum. 
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5.6 Reverse-transcriptase polymerase chain reaction 
PBMEC/C1-2 and primary cells were seeded at cell density of 5 x10
4
 per well in a 6-well 
plate. Cells were subsequently and transferred into a GenElute Total RNA mini prep kit 
filtration column and centrifuged at 12,000g for 2 minutes. The lysate was transferred into a 
new column and centrifuged at 12,000g for 2 minutes. The column was washed twice with 
wash solution and 50 µL of the elution solution was added into the binding column and 
centrifuged. The concentration of total extracted RNA was quantified using a Nanodrop 
system (Thermo Scientific, Nanodrop 1000).   
RNA amplification was conducted using the My Taq One-Step RT-PCR kit according to the 
manufactures instructions. The PCR primers used were as follows: β-actin (accession 
number: AY550069) forward primer 5’- AAGCCAACCGTGAGAAGATG and reverse 
primer 5’- CAACTAACAGTCCGCCTAGAAG; BCRP (accession number: NM_214010) 
forward primer 5’- TCCGACCACCATGACAAATC, reverse primer 5’- 
GTACACCGAGCTCTTCTTCTTC.  The thermal cycle was run as recommend by the 
manufacturer’s kit and the amplified products were separated and visualised using a 1% 
agarose gel stained with ethidium bromide.  
5.7 Immunofluorescence detection of BCRP 
For PBMEC/C1-2 20,000 cells were seeded onto gelatin coated glass cover slips and allowed 
to adhere for 48 hours.  For primary PBMEC, 1.0 x10
5 
cells/cm
2 
were seeded onto collagen 
(300 μg/mL)-fibronectin (7.5 μg/mL) coated 12-well permeable insets (Greiner ThinCert
®
) 
and grown for 4 days. The cover slips were subsequently washed with phosphate buffered 
saline (PBS), fixed with methanol at -20 °C for 20 minutes before being blocked with 1 % 
BSA in PBS for 30 minutes.  Cells were subsequently incubated with Anti-BCRP antibody 
(1:400) for 2 hours at 37 °C and goat anti-rabbit IgG-FITC (1:500) for 45 minutes at room 
temperature before being mounted with DAPI-containing mounting media. Cover slips were 
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subsequently analysed in an upright confocal microscope (Leica SP5 TCS II MP) and 
visualised with a 40x oil immersion objective. Images were acquired using an argon laser at 
494 nm to visualise FITC and a helium–neon laser to visualise DAPI at 461 nm.  
5.8 Selection of modulators  
Modulators were selected based on our previous screening with choroid epithelial cells 
21
 and 
included: apigenin, baicalin, biochanin A, chrysin, curcumin, 17-β-estradiol, fisetin, flavone, 
hesperidin, hesperetin, indole-3-carbinol (I3C), α-napthoflavone, naringin, quercetin, 
reservatrol, rutin, silymarin and 6,2,4-trimethoxyflavone (TMF). 
5.9 Modulator induced cellular toxicity  
For PBMEC/C1-2, 6 x10
4
 cells per well were seeded into the 96-well plate and allowed to 
attach for 24 hours followed by incubation with modulators (0.001-1000 µM) for 24 hours. 
Thereafter 20 µL per well of a 5 mg/mL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) solution was added and incubated at 37°C 5% CO2 for 4 hours followed by 
the addition of 100 µL per well of DMSO and the UV-absorbance of the formazan product 
determined at a UV-absorbance of 595 nm.  Results were expressed as percentage 
cytotoxicity relative to a control (exposed to 0.5% DMSO only) and the IC50 was 
subsequently calculated using a sigmoidal dose response function within the Graphpad Prism 
version 5.0 (GraphPad Software, Inc. USA).  For PBMEC, two concentrations were selected 
based on the outcome of the studies with C12 cells. 
5.10 Hoechst 33342 intracellular accumulation assay  
The potential for modulators to alter the activity of BCRP was then assessed by measuring 
changes in the intracellular accumulation of H33342 in the absence and presence of 
modulators. 2 x10
4
 cells PBMEC/C1-2 cells were seeded onto clear-bottomed 96-well plates 
for 24 hours. To assess the potential for direct inhibition of BCRP function, cells were pre-
treated with 25 μM of modulators (unless or otherwise stated) and incubated at 37 °C for 1 
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hour. Cells were also incubated with 1 μM Ko143 for 1 hour (used as a positive inhibitor 
control comparator) or 25 μM tert-butyl hydroquinone (TBHQ) (used as a positive inducer 
control comparator)
40, 73
.  Following pre-incubation with modulators or Ko143, media was 
replaced with fresh media containing 10 μM H33342 and 25 μM of modulators (unless 
otherwise indicated) and incubated for a further 30 minutes.  Thereafter cells were washed 
twice with ice cold PBS and lysed at -80°C for 20 minutes before being resuspended in 100 
μL of water and fluorescence measured with dual-scanning microplate spectrofluorometer 
(Spectra Max Gemini XS, molecular devices, Sunnyvale, California) at an excitation 
wavelength of 355 nm and emission wavelength of 460 nm.  
To assess the potential for long-term BCRP modulation (possibly through 
transcriptional/translation effects), cells were pre-incubated with 25 μM of modulators 
(unless otherwise stated) for 24 hours in PBMEC media at 37°C. Following pre-incubation, 
the cells were treated as described above. 
5.11 Modulation of BCRP protein expression 
In an attempt to assess the impact of modulators on BCRP protein expression and confirm 
observations from the H33342 intracellular accumulation assay, PBMEC/C1-2 cells were 
grown to confluency and treated with 25 µM of modulator (unless otherwise stated) for 24 
hours. Cells were subsequently treated with 0.5% trypsin-EDTA to obtain whole cell lysates. 
The obtained cell suspension was centrifuged at 2,000 rpm for 5 minutes and the pellet was 
incubated with 40 µL radioimmuniprecipitation (RIPA) lysis buffer (Santa Cruz 
Biotechnology, Texas, USA) before being homogenised by ultra-sonication on ice. The 
resultant cell debris was then removed by centrifugation at 16,000g and 4 °C for 30 minutes 
and the supernatant protein content determined by a bicinchoninic acid assay (BCA).  
70 µg of protein was subsequently loaded into each well of a 8 % pre-cast SDS-PAGE gel 
(Optiblot, Abcam) and gel electrophoresis conducted according to the manufacturer’s 
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instructions (Optiblot Electrophoresis Kit, Abcam).  Proteins were transferred onto a PVDF 
membrane and blotted before being blocked with 5 % milk powder in TBST for 1 hour at 
room temperature and incubated with anti-BCRP (Sigma-Aldrich, UK) for 24 hours at 4°C 
(1:4000) and goat anti-rabbit IgG conjugated horseradish peroxidase (1:7500). β-actin 
loading control was detected by HRP-conjugated beta-actin antibody (C4) (1:7500).  All 
bands were subsequently visualised by an incubation with an enhanced chemiluminescence 
(ECL) solution (90mM p-coumaric acid, 250mM luminol, 1M tris and 30% H2O2) before X-
ray film development.  The functional consequences of changes in BCRP expression were 
subsequently assessed in an in-vitro permeable insert model. 
5.12 Quantitative polymerase chain analysis 
RNA obtained from PBMEC/C1-2 were reverse transcribed using a Nanoscript reverse 
transcription kit (PrimerDesign, UK). Gene detection analysis was conducted using a SYBER 
green Precision Master Mix (PrimerDesign, UK) and a custom designed gene detection kit 
for BCRP (PrimerDesign, UK).  The house keeping gene used was HPRT1 (accession 
number: DQ845175) forward primer 5’- GGTCAAGCAGCATAATCCAAAG and reverse 
primer 5’-CAAGGGCATAGCCTACCACAA). To assess modulator-mediated genomic 
changes BCRP, modulators showing up- or down-regulation of BCRP protein were selected 
and incubated with PBMEC/C1-2 cells (seeded at cell density of 5 x10
4
 per well in a 6-well 
plate) for 24-hours prior to RNA extraction and qPCR analysis. BCRP expression in 
PBMEC/C1-2 and primary cells was also confirmed through non-modulator control wells 
(0.5 % DMSO).  Results are presented as BCRP normalised RNA levels (arbitrary units) 
normalised to HPRT1 using relative with a 2
^ddCT
 method used to describe the fold-change 
compared to untreated samples. 
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5.13 AhR mediated regulation of BCRP in PBMEC/C1-2 
Dicer siRNA duplexes were custom synthesised by IDTDna for targeting of porcine AhR 
(NM_001303026); sense: 5’-ACACAUUGAAAUAGGUGCCUUAUUCUU-3’ and 
antisense: 3’-TGUGUAACUUUAUCCACGGAAUAAG-5’.  Cell density and transfection 
efficacy was optimised using a fluorescently tagged siRNA control duplex (TYE
®
 563).  
PBMEC/C1-2 were seeded into a 12-well plate at a seeding density of 100,000 cells/well and 
allowed to attach for 24 hours. Cells were subsequently washed and siRNA duplex prepared 
with the cationic transfection reagent TransIT (Mirus Bio, Madison, USA) according to 
manufacturer’s instruction and incubated with cells (10 nM final concentration) for 12-hours.  
In addition to the use of siRNA downregulate AhR, chemical downregulation was assessed by 
incubating cells with the AhR antagonist CH223191 at a concentration of 1 µM and 10 µM 
for 24 hours. Subsequent changes in AhR and BCRP gene expression following siRNA 
silencing or CH223191 downregulation were assessed using qPCR. The modulation of BCRP 
and AhR gene expression was further assessed following the incubation of modulators 
identified as possible BCPR inducers/down-regulators from western blotting studies, for 24 
hours following silencing of AhR. 
5.14 Luciferase activation assay 
To assess the potential of modulators to activate AhR pathways, H1L6.1c2 cells were seeded 
into 96-well plates at a seeding density of 75,000 cells/well and allowed to attach overnight.  
The activation of AhR was confirmed by exposure to a 7-fold log concentration range 
(0.0001-1000 µM) of the known AhR activator omeprazole for 24 hours.  Cell were washed 
with warm PBS before 20 µL 1X Lysis Buffer (Promega) was added to each well and the 
plates shaken for 20 minutes (1000 rpm) on an orbital plate shaker.  20 µL of the cell lysate 
was then transferred into wells of an opaque 96-well plate and 100 µL of the Luciferase 
Assay Reagent was added per well. The luminescence was read immediately and at 10 
29 
 
seconds intervals for a duration of 60 seconds (SpectraMax MX5 reader: Molecular Devices 
LLC, Sunnyvale, CA).  Modulators were prepared at a fixed optimal concentration 
(determined from the H33342 intracellular accumulation assay) and the assay conducted as 
described above.  Results are presented as percent activation relative to the maximum 
response from omeprazole. 
5.15 Functional expression of BCRP in an in vitro permeable insert BBB model 
For assessing the functional consequences of a change in BCRP protein expression, 
modulators were incubated for 24 hours in fresh maintenance media in both compartments, 
prior to the addition of fresh SFM containing 10 µM pheophorbide (PhA) only into the apical 
compartment and SFM into the basolateral compartment. For assessing the ability to inhibit 
BCRP function, modulators (or 1 µM Ko143) were preincubated with monolayers in SFM for 
30 minutes in both apical and basolateral compartments.  Thereafter the media was replaced 
in the apical compartment with SFM containing modulator (or Ko143) and 10 µM PhA, and 
SFM only into the basolateral compartment. For assessing BCRP inducers, PhA was added 
into the basolateral compartment. Samples were taken from the inner (inducers) or outer 
(inhibitor/downregulator) well at 0, 30, 60, 90, 120, 150 and 180 minutes and  replaced with 
fresh warm SFM with PhA concentrations analysed using a fluorescent plate reader 
(SpectraMax MX5 reader, Molecular Devices LLC, Sunnyvale, CA) with an excitation 
wavelength of 410 nm and emission of 675 nm. 
The apparent permeability coefficient (Papp) was calculated according to equation 1: 
 
Papp=
dQ
dt
×
1
AC0
        (1) 
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where dQ/dt the amount of drug permeated per unit of time and is calculated from the 
regression line of time points of sampling, A (cm
2
) is the insert surface area available for 
permeation and C0 the initial drug concentration in the donor compartment. 
5.15 Statistical Analysis 
All statistical analyses were performed in Graphpad Prism (La Jolla, California, USA). One-
way ANOVA and t-tests were carried out to determine the differences between the mean 
values. For all multi-well based assay replicates of at least 6 were used in three independent 
experiments. For western blot and transport studies replicates of at least three were used and 
repeated in three independent experiments. IC50 and EC50 metrics were calculated using 
sigmoidal fit functions within Graphpad Prism. A significance p-value of < 0.05 was 
considered as statistically significant.  
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Figure Legend 
Figure 1.  Expression and localisation of BCRP in cells. (A) Amplicon products for loading 
control (ACTB) and BCRP; (B) localisation of BCRP in PBMEC/C1-2 and (C) localisation 
of BCRP in and PBMEC (‘60s’ fraction).  Cells were grown on the coverslips for 2-3 days 
(PBMEC/C1-2) or permeable inserts (PBMEC), fixed with methanol at -20 °C for 20 minutes 
and stained for BCRP using the anti-ABCG2 primary antibody and goat anti-rabbit IgG-FITC 
secondary antibody (Green). Cell nuclei were visualized using DAPI (Blue). Negative: 
excludes anti-ABCG2 antibody but includes FITC secondary; Positive: includes primary and 
secondary antibodies. Unless otherwise states an objective lens of 40x was used. 
Figure 2. Cellular cytotoxicity of modulators of BCRP on PBMEC/C1-2. Cells were seeded 
and grown on a 96-well plate for 48 hours prior to exposure to modulators over a 
concentration range of 0.001-1000 µM for 24 hours. Subsequently 20µl of MTT was added 
into each well and the plate incubated for 4 hours. The media was aspirated and 100 µl of 
DMSO was added before the absorbance of each well was read at 595 nm. Data presented for 
each modulator is reported as result from up to 8 replications per compound in three 
independent experiments. ND: not determined. 
Figure 3. Cellular cytotoxicity of modulators of BCRP on primary PBMEC. Cells were 
seeded and grown on a 96-well plate for 48 hours prior to exposure to modulators at 25 µM 
and 100 µM for 24 hours. Subsequently 20µl of MTT was added into each well and the plate 
incubated for 4 hours. The media was aspirated and 100 µl of DMSO was added before the 
absorbance of each well was read at 595 nm. Data presented for each modulator is reported as 
result from up to 8 replications per compound in three independent experiments.  
Figure 4. H33342 accumulation assay for BCRP function in PBMEC/C1-2 cells. Cells were 
grown in a 96 well plate for 48 hours and subsequently washed with HBSS.  Cells were then 
incubated for 1 hour (A) or 24 hours (B) with media containing 0.01-1 µM or 1-100 µM (as 
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indicated) of test compound.  At the end of the incubation period, cells were washed with ice 
cold HBSS and incubated with media containing H33342 for 1 hour.  Cells were lysed and 
the intracellular accumulation of H33342 assessed by measuring its absorbance on a 
fluorescent plate reader (Excitation and emission wavelength of 350 nm and 490 nm 
respectively). Data is represented as intracellular H33342 accumulation (normalised to 
control) and reported as mean ± SD, with control being equivalent to a value of 1.0 on the y-
axis.  Grey shaded areas represent the fold-change range with Ko143 (1 µM) (upper panel) or 
TBHQ (25 µM) (lower panel) for comparison.   Statistical significance was conducted 
relative to control,  * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001 and **** P ≤ 0.0001.  # indicates 
phytochemicals not analysed due to their auto-fluorescence properties. 
Figure 5. (A) Western blot protein expression of β-actin and BCRP. (B) Western blot results 
of modulator incubation with PBMEC/C1-2. (C) Fold-change in BCRP protein expression.  
Modulators were exposed to cells for 24-hours in culture prior to extraction of protein. 
Modulator concentrations of 25 µM were utilised, except for curcumin, 17-β-estradiol, α-
napthoflavone, baicalin, hesperetin and hesperedin (1 µM).  Whole cell lysate (70 µg/lane) 
were separated on an 8% SDS-Polyacrylamide gel and proteins transferred onto a PVDF 
membrane and incubated with a 1:4000 dilution of the BCRP primary antibody (anti-
ABCG2) overnight followed by a 1:7500 dilution of a HRP-conjugated secondary antibody 
for 2 hours before development using a ECL method.   For detection of the control (β-actin) 
membranes were incubated with a 1:7500 dilution of HRP-conjugated β-actin primary 
antibody overnight and detected by the ECL method. Data is represented as mean ± SD of 
three independent experiments with statistically significant differences between control (fold 
change = 0) and modulator exposed conditions indicated as * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 
0.001 and **** P ≤ 0.0001, N=4. 
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Figure 6: Modulation of AhR and BCRP gene expression  
PBMEC/C1-2 cells were seeded onto a 24-well plate and incubated with (A) modulators 
alone, (B) siRNA or CH223191 (1 and 10 µM) and quercetin (25 µM), naringin (25 µM), 
curcumin (1 µM) and 17-β-estradiol (1 µM) for 24 h to assess changes in AhR (C) or BCRP 
(D).  RNA was extracted and changes in gene expression determined using qPCR and 
calculated relative to normalised control samples (absence of modulator, siRNA or 
CH223191).  Significant differences between control and siRNA or CH223191 exposed 
samples are indicated above the appropriate error bars.  Significant differences between each 
untreated/control condition and each modulator condition is indicated by stars above the error 
bars.  Significant difference in the absence and presence of siRNA are indicated above 
identifier lines. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001 and **** P ≤ 0.0001. N=3. 
Figure 7:  The activation of AhR by phytochemical modulators. 
H1L6.1c2 cells were seeded to a 96-well plate and incubated with modulators for 24 h and 
CALUX assay was performed. Modulator concentrations of 25 µM were utilised, except for 
curcumin, 17-β-estradiol, α-napthoflavone, baicalin, hesperetin and hesperedin (1 µM).  
Using the luminescence quantified from the maximum activation of AhR by omeprazole 
(data not shown), the activation of AhR by modulators was reported as percentage maximum 
omeprazole induction.  To simplify the analysis, activation between 1-25 % was classified as 
‘minimal’ with values of greater than 75 % being classified as ‘strong’ activators of AhR. 
Eight replicates were used per modulators and replicated across three independent 
experiments. 
Figure 8: Cumulative transport of PhA across an in-vitro BBB model. 
Cells were grown on permeable inserts and transport studies were performed on day 4 in the 
absence or presence of Ko143 (1 µM) or modulators (down-regulators: 1 µM curcumin and 1 
µM 17-β-estradiol; up-regulators: 25 µM naringin and 25 µM quercetin).  The apical 
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compartment was selected as the donor compartment in all studies except for up-regulators, 
where the basolateral was selected as the donor compartment.  Statistically significant 
differences between control and Ko143/modulators samples at each data point are indicated. 
* P ≤ 0.05.  N=5. 
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Tables 
Table 1. Apparent permeability of PhA in the absence and presence of modulators of BCRP 
 
 
  PBMEC/C1-2 Primary PBMEC 
  Papp (x10
-6
 cm/s) 
PhA (AB) 7.86 ± 0.23 4.82 ± 0.47 
PhA (BA) 44.13 ± 0.31 
***
 54.12 ± 1.08 
***
 
+Ko143 (AB) 17.85 ± 0.32 14.75 ± 0.89 
+Ko143 (BA) 30.77 ± 0.58 
***
 24.75 ± 1.21 
**
 
+17-β-Estradiol (AB) 32.74 ± 0.34 
***
 33.18 ± 3.25 
**
 
+Curcumin (AB) 40.08 ± 0.65 
***
 29.88 ± 0.89 
***
 
+Quercetin (BA) 63.21 ± 0.54 
**
 66.18 ± 1.98 
*
 
+Naringin (BA) 59.23 ± 0.29 
**
 58.26 ± 1.23 
 
Papp measured in the apical to basolateral flux direction.  BA indicates studies where the 
donor compartment is the basolateral and the flux is determined in the basolateral to apical 
direction. Statistical differences are indicated in superscript and are in comparison to 
associated PhA transport in AB or BA directions : 
*
 p < 0.05; 
**
 p < 0.01; 
***
 p < 0.001 
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Highlights 
· Naringin and quercetin induced BCRP expression and function 
· Curcumin and 17-β-estradiol down-regulated BCRP expression and function 
· 2,6,4-trimethoflavone is a potent inhibitor of BCRP function 
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